Source-grounded facts extracted from Inspire Medical Systems, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Michael H. Carrel was appointed as Class III Director at Inspire Medical Systems, Inc..
“On July 20, 2026, the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Michael H. Carrel to the Board, effective immediately.”
Inspire Medical Systems, Inc. shareholders approved Approval of an amendment and restatement of the Inspire Medical Systems, Inc. 2018 Incentive Award Plan (A&R 2018 Plan) at the 2026-04-30 meeting.
“As reported below under Item 5.07 of this Current Report on Form 8-K (this “Current Report”), on April 30, 2026, Inspire Medical Systems, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company’s stockholders approved an amendment and restatement of the Inspire Medical Systems, Inc. 2018 Incentive Award Plan (such amended and restated plan, the “A&R 2018 Plan”).”
Inspire Medical Systems, Inc.: Amendment to Certificate of Incorporation to phase out classified board structure and provide for annual election of all directors beginning with 2029 annual meeting, effective May 1, 2026 (effective 2026-05-01).
“On May 1, 2026, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which became effective upon filing.”
Inspire Medical Systems, Inc. reported Full Year 2026 results: revenue in the range of $825 million to $875 million, EPS diluted EPS in the range of $0.07 to $0.62 and adjusted diluted EPS in the range of $0.75 to $1.25. Guidance lowered.
“The Company is revising its previously announced revenue outlook to be in the range of $825 million to $875 million, which represents a decline of 4% to 10% compared to 2025. Additionally, the Company now expects annual adjusted operating margin in the range of 2% to 4%, diluted EPS in the range of $0.07 to $0.62 and adjusted diluted EPS in the range of $0.75 to $1.25.”
Inspire Medical Systems, Inc. reported the quarter ended March 31, 2026 results: revenue $204.6 million, net income Net loss was $11.3 million, EPS Diluted EPS was $(0.39) and adjusted diluted EPS was $0.10.
“Revenue increased 1.6% to $204.6 million, primarily driven by increased market penetration, offset by the adverse effects of reimbursement disruption and the Wasteful and Inappropriate Service Reduction (WISeR) program. • Gross margin increased 180 bps to 86.5%, primarily due to increased sales mix of the Inspire V system, which has a higher gross margin than the Inspire IV system. • Operating expenses increased $5.9 million, or 3.4%, to $178.0 million, primarily driven by higher marketing expenses, legal fees and employee-related costs, partially offset by lower R&D expenses. • Operating loss decreased $0.4 million to $1.1 million, and operating margin was (0.5)%. Adjusted operating income was $0.3 million, and adjusted operating margin was 0.2%. • Interest and dividend income decreased by $1.3 million, primarily due to lower average interest rates and lower average cash, cash equivalents, and investment balances. • The effective tax rate was 571.2% compared to 28.1%. The increase in”
Inspire Medical Systems, Inc.: Amended and Restated Bylaws approved by the Board, subject to and effective upon stockholder approval of the Proposed Charter Amendment, removing the provision that directors may be removed only for cause (effective 2026-02-05).
“On February 5, 2026, the Board approved the Amended and Restated Bylaws of the Company (the “Amended Bylaws”), subject to and effective upon the approval of the Proposed Charter Amendment by the stockholders at the Company’s 2026 Annual Meeting.”
Inspire Medical Systems, Inc.: Proposal to declassify the Board of Directors and provide for annual election of directors following a phase-in period, subject to stockholder approval at the 2026 Annual Meeting.
“The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).”
Philip J. Ebeling resigned as Chief Operating Officer at Inspire Medical Systems, Inc..
“On July 18, 2024, Philip J. Ebeling notified Inspire Medical Systems, Inc. (the “ Company ”) of his decision to resign as Chief Operating Officer of the Company, effective as of August 9, 2024, in order to pursue a new professional opportunity as President and Chief Executive Officer of a private medical device company operating in the cardiology space.”
Inspire Medical Systems, Inc. shareholders approved Approval, on an Advisory (Non-Binding) Basis, of the Compensation of the Company's Named Executive Officers at the 2024-05-02 meeting.
“Proposal 3 — Approval, on an Advisory (Non-Binding) Basis, of the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers by voting as follows:”
Inspire Medical Systems, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2024-05-02 meeting.
“Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024 by voting as follows:”
Inspire Medical Systems, Inc. shareholders approved Election of Class III directors at the 2024-05-02 meeting.
“Proposal 1 — Election of Directors The following director nominees were elected as Class III directors to hold office until the Company’s annual meeting of stockholders to be held in 2027 and until their respective successors have been duly elected and qualified.”
Inspire Medical Systems, Inc. reported the full year 2024 results: revenue $783 million to $793 million. Guidance raised.
“Inspire is initiating first-time diluted net income per share guidance for the full year 2024 of between $0.10 to $0.20 per share.”
Inspire Medical Systems, Inc. reported the quarter ended March 31, 2024 results: revenue $164.0 million, net income $10.0 million net loss, EPS $0.34 per share net loss per share.
“Revenue was $164.0 million for the three months ended March 31, 2024, a 28% increase from $127.9 million in the corresponding period in the prior year.”
Inspire Medical Systems, Inc. reported the quarter and year ended December 31, 2023 results: revenue $192.5 million, net income $14.8 million, EPS $0.49. Guidance reaffirmed.
“sleep apnea, today reported financial results for the quarter and year ended December 31, 2023. Recent Business Highlights and Full Year 2024 Guidance • Generated revenue of $192.5 million in the fourth quarter of 2023, a 40% increase over the same quarter last year, and revenue of $624.8 million in full year 2023, a 53% increase over full year 2022 • Achieved”
Gary Ellis was appointed as Lead Independent Director at Inspire Medical Systems, Inc..
“The Board has appointed Gary Ellis to the role of Lead Independent Director to be effective at the conclusion of the 2024 Annual Meeting.”
Timothy P. Herbert was appointed as Board Chair at Inspire Medical Systems, Inc..
“the Board has appointed Chief Executive Officer Timothy P. Herbert to the additional role of Board Chair, succeeding Ms. Nelson, to be effective at the conclusion of the 2024 Annual Meeting.”
Marilyn Carlson Nelson departed as Chair of the Board of Directors at Inspire Medical Systems, Inc..
“Marilyn Carlson Nelson, Chair of the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), notified the Company of her decision to retire from the Board and not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) scheduled to occur on May 2, 2024.”
Jerry C. Griffin departed as Director at Inspire Medical Systems, Inc..
“On January 22, 2024, Jerry C. Griffin, M.D., a member of the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), notified the Company of his decision to retire from the Board and not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).”
Inspire Medical Systems, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue Revenue for the fourth quarter of 2023 is anticipated to be in the range of $192.3 million to $192.5 million. Guidance initiated.
“Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance”
Myriam J. Curet, M.D. was appointed as Director at Inspire Medical Systems, Inc..
“On December 21, 2023, the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Myriam J. Curet, M.D., to the Board, effective immediately.”
Inspire Medical Systems, Inc. reported full year 2023 results: revenue $608 million to $612 million. Guidance raised.
“Inspire is increasing and narrowing its full year 2023 revenue guidance to between $608 million to $612 million, which represents growth of 49% to 50% over full year 2022 revenue of $407.9 million. This compares to the prior revenue guidance of $600 million to $610 million.”
Inspire Medical Systems, Inc. reported quarter ended June 30, 2023 results: revenue $151.1 million, net income $12.0 million, EPS $0.41 per share. Guidance raised.
“Revenue was $151.1 million for the three months ended June 30, 2023, a 65% increase from $91.4 million in the corresponding period in the prior year. U.S. revenue for the quarter was $144.7 million, an increase of 65% as compared to the prior year quarter. Second quarter revenue outside the U.S. was $6.3 million, an increase of 81% as compared to the second quarter of 2022. Gross margin was 83.9% for the three months ended June 30, 2023, compared to 84.5% for the corresponding prior year period, with the reduction primarily due to additional manufacturing costs of sensors and lower yields prior to process enhancements, and higher costs of certain component parts, partially offset by the price increase that began in May of 2022. Operating expense increased to $143.4 million for the second quarter of 2023, as compared to $91.2 million in the corresponding prior year period, an increase of 57%. This increase primarily reflected ongoing investments in the expansion of the U.S. sales organi”
Charisse Y. Sparks, M.D. resigned as Director at Inspire Medical Systems, Inc..
“In connection with her appointment as Chief Medical Officer of the Company, on July 27, 2023, Dr. Sparks resigned from the Board of Directors, including the Nominating and Corporate Governance Committee, effective upon the commencement of service as Chief Medical Officer.”
Charisse Y. Sparks, M.D. was appointed as Chief Medical Officer at Inspire Medical Systems, Inc..
“On July 31, 2023, the Company announced that Charisse Y. Sparks, M.D., was appointed to serve as its Chief Medical Officer, effective July 27, 2023.”
Inspire Medical Systems, Inc. shareholders approved Advisory Vote on Approval of the Compensation of the Company's Named Executive Officers at the 2023-04-27 meeting.
“Item 3 — Advisory Vote on Approval of the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers by voting as follows: Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 22,660,463 2,795,344 58,322 1,883,022”
Inspire Medical Systems, Inc. shareholders approved Ratification of the Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for 2022 at the 2023-04-27 meeting.
“Item 2 — Ratification of the Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for 2022 The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 by voting as follows: Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 26,301,995 1,078,471 16,685 —”
Inspire Medical Systems, Inc. shareholders approved Election of Class II directors at the 2023-04-27 meeting.
“Item 1 — Election of Directors The following Class II directors were elected for a term of office expiring on the date of the Company’s annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified. The number of votes cast for and withheld from each nominee and the number of broker non-votes with respect to each nominee were as follows: Votes FOR Votes WITHHELD Broker Non-Votes Cynthia B. Burks 25,322,663 191,466 1,883,022 Gary L. Ellis 15,916,171 9,597,958 1,883,022 Georgia Garinois-Melenikiotou 25,049,945 464,184 1,883,022 Dana G. Mead, Jr. 24,971,294 542,835 1,883,022”
Inspire Medical Systems, Inc. reported the quarter ended March 31, 2023 results: revenue $127.9 million, net income $15.4 million, EPS $0.53 per share. Guidance raised.
“Revenue was $127.9 million for the three months ended March 31, 2023, an 84% increase from $69.4 million in the corresponding period in the prior year. U.S. revenue for the quarter was $124.5 million, an increase of 87% as compared to the prior year quarter. First quarter revenue outside the U.S. was $3.4 million, an increase of 15% as compared to the first quarter of 2022. Gross margin was 84.4% for the three months ended March 31, 2023, compared to 85.6% for the corresponding prior year period, with the reduction primarily due higher costs of certain component parts somewhat offset by the May 2022 price increase which is substantially in effect across our U.S. customer base. Operating expense increased to $127.5 million for the first quarter of 2023, as compared to $75.4 million in the corresponding prior year period, an increase of 69%. This increase primarily reflected ongoing investments in the expansion of the U.S. sales organization, direct-to-patient marketing programs, continu”
Inspire Medical Systems, Inc. reported full year 2023 results: revenue $560 million to $570 million. Guidance initiated.
“Inspire expects full year 2023 revenue to be in the range of $560 million to $570 million, which would represent growth of approximately 37% to 40% over full year 2022 revenue of $407.9 million.”
Inspire Medical Systems, Inc. reported the fiscal year ended December 31, 2022 results: revenue $407.9 million, net income $44.9 million, EPS $1.60.
“Highlights and Full Year 2023 Guidance • Generated revenue of $137.9 million in the fourth quarter of 2022, a 76% increase over the same quarter last year, and revenue of $407.9 million in full year 2022, a 75% increase over full year 2021 • Achieved gross margin of 83.9% in the fourth quarter of 2022 • Reported net income of $3.2 million and diluted net”
Inspire Medical Systems, Inc. reported the quarter ended December 31, 2022 results: revenue $137.9 million, net income $3.2 million, EPS $0.10.
“Revenue was $137.9 million for the three months ended December 31, 2022, a 76% increase from $78.4 million in the corresponding period in the prior year.”
Inspire Medical Systems, Inc. updated its the quarter and fiscal year ended December 31, 2022 guidance (reaffirmed).
“On February 7, 2023, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2022.”
Inspire Medical Systems, Inc. reported preliminary financial results for quarter and full year ended December 31, 2022.
“On January 9, 2023, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing certain preliminary and unaudited results for the quarter and full year ended December 31, 2022.”
Inspire Medical Systems, Inc. reported quarter ended September 30, 2022 results: revenue $109.2 million. Guidance raised.
“solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2022. Recent Business Highlights • Generated revenue of $109.2 million in the third quarter of 2022, a 77% increase over the same quarter last year • Achieved gross margin of 81.9% in the third quarter of 2022 • Activated 59 new centers in the U.S.”
Charisse Y. Sparks, M.D. was appointed as Director at Inspire Medical Systems, Inc..
“expanded the size of the Board to eleven directors, and appointed Cynthia Burks and Charisse Y. Sparks, M.D. to the Board, effective immediately.”
Cynthia Burks was appointed as Director at Inspire Medical Systems, Inc..
“expanded the size of the Board to eleven directors, and appointed Cynthia Burks and Charisse Y. Sparks, M.D. to the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.